ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ziopharm Oncology (ZIOP) Posts Q1 Loss of 69c/Share
May 7, 2015 4:42 PM EDTZiopharm Oncology (NASDAQ: ZIOP) reported Q1 EPS of ($0.69), $0.56 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $272 thousand versus the consensus estimate of $130 thousand.
Recent and Upcoming Corporate Highlights
In January, ZIOPHARM and its partner, Intrexon Corporation, entered into an exclusive license agreement with The University of Texas MD Anderson Cancer Center for programs and associated technologies related to the development of non-viral adoptive cellular therapies, including CAR T, TCR and associated cell-based therapies. When combined with Intrexon's technology suite and ZIOPHARM's further clinical validation of the RheoSwitch... More
